DVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DaVita Inc (DVA) is not a strong buy for a beginner investor with a long-term focus at this moment. While the company shows some positive financial growth trends and analyst upgrades, the technical indicators are neutral, and there is significant insider and hedge fund selling activity. Additionally, the lack of strong proprietary trading signals and mixed options sentiment suggests waiting for a clearer entry point.
The MACD histogram is negative (-0.846) and contracting, indicating weak momentum. RSI is neutral at 45.759, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 148.298, with resistance at 152.089 and support at 144.506.
Analyst upgrades with increased price targets, strong Q4 revenue growth (+9.87% YoY), improved gross margin (+4.09% YoY), and EPS growth (+6.47% YoY). Healthcare sector highlighted as a focus area by Citigroup.
Significant insider selling (+267.89% last month) and hedge fund selling (+6939.07% last quarter). Net income dropped (-9.68% YoY) despite revenue growth. No recent congress trading data or strong proprietary trading signals.
In Q4 2025, revenue increased by 9.87% YoY to $3.62 billion, gross margin improved to 28.28% (+4.09%), and EPS grew by 6.47% to 3.29. However, net income declined by 9.68% YoY to $234.2 million.
Analysts have raised price targets, with UBS setting the highest at $190, citing strong 2026 guidance and EPS growth driven by operational improvements and acquisitions. However, most ratings remain Hold, reflecting cautious optimism.
